The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

On August 2, 2022, Heron Therapeutics Inc. (Heron) initiated a nationwide recall for a single lot of **ZYNRELEF, 400 mg bupivacaine and 12 mg meloxicam.** This includes correction or removal of the affected product to the point of care level in the United States. The affected product lot **01126739** was distributed under the label of Heron Therapeutics, Inc. No other lots are impacted.

NDC	**Lot**	**Exp. Date**	**Size**	**Correct Syringe Part Number**	**Incorrect Syringe Part Number**	**Heron Distribution Dates**
47426-301-02	01126739	31Jul2023	400 mg/12 mg kit	4100-X00V0	4100-000V0	16Jun2022 – 30Jun2022

This action has been initiated because the incorrect syringe was mistakenly packaged in a portion of one lot of ZYNRELEF 400 mg/12 mg kits. It is unlikely that the incorrect syringe will be used because it is anticipated that the incorrect syringe will be identified by the person preparing the product. If the incorrect syringe is used, the health hazard that the Luer lock applicator (LLA) may come off during surgical application and lead to a delay in administration of product is negligible with no disability or physical complaints anticipated. No additional hazards are anticipated as the LLA is not expected to cause injury if it comes off because it is sterile with no sharp edges and would be immediately identified and removed from the surgical site. To date, Heron has not received any adverse event reports related to the incorrect syringe or involving the impacted lot.